L ichen planus (LP) (
) is a common, chronic inflammatory mucocutaneous disease that affects mainly middle-aged adults, the prevalence being greater among women. The oral mucosa, skin, genital mucosa, and nails are commonly involved, in any combination. The clinical features of oral LP (OLP) are generally polymorphic and usually consist of bilateral and/or multiple symmetrical lesions, such as reticular, plaque-like, papular, atrophic, erosive, and bullous, and these are categorized into 6 types. 1 In particular, erosive and atrophic forms of OLP manifest painful symptoms, with weight loss and poor quality of life, and have the potential of malignant transformation.
lesional T-cell clones may be blocked partially by anti-major histocompatibility complex class I monoclonal antibody. 5 The cause of OLP is unknown, but it seems to be triggered by stress; genetics; allergic reactions to medicines or dental materials; and by viral infections, such as with hepatitis C virus (HCV). 6 It has been shown that chronic HCV infection, in addition to causing liver disease, is responsible for several extrahepatic manifestations and immune abnormalities, including hematologic, renal, and mucocutaneous diseases. [7] [8] [9] Replication of HCV in the oral mucosa 10 and presence of HCV-specific T cells in OLP specimens 11, 12 could be involved in the pathogenesis of OLP. Three recent independent metaanalyses provide robust evidence that LP and HCV are associated. [13] [14] [15] In particular, the relationship between OLP and HCV has been suggested by studies from Japan and Mediterranean countries, indicating a strong geographic relationship. 16, 17 The differences with respect to geographic area could be associated with the different genetic susceptibility of the hosts. HCV-associated OLP may be subdivided into distinct subtypes, because studies have shown an increased frequency of the HLA class II allele group, DR6, in patients with OLP with HCV compared with those without HCV (52% vs 18%; P ¼ .028; relative risk, 4.93). 18, 19 The HLA-DR6 allele group is frequently observed in Italian patients with OLP and hepatitis C.
HCV infection is a major public health problem because it causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. In Japan, elderly patients are at a higher risk for hepatocellular carcinoma, and HCV eradication has a smaller effect on hepatocarcinogenesis in older patients. 20 OLP can appear or be exacerbated during interferon (IFN) therapy for chronic hepatitis C. 21, 22 The genome-wide association study (GWAS) has become a powerful tool for investigating the human genetic basis of various diseases. Various genome-based host variants, such as IFNL3 (also known as IL28B) [23] [24] [25] and inosine triphosphatase (ITPA) 26 genes, have been found to be valuable markers for treatment response to hepatitis C and predicting spontaneous viral clearance.
The purpose of this study was to identify the host genetic factors for HCV-related LP in the Japanese and Italian populations.
Materials and Methods

Ethical Considerations
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of Saga Medical School, Kurume Medical School, and each participating medical center. Written informed consent for participation in the study was obtained from each patient and all samples were anonymized. All the applied methods in this study were carried out in accordance with the approved guidelines.
Study Group and Samples
Genomic DNA samples were collected from HCVinfected Japanese patients with LP (71 patients; mean age AE standard deviation, 67.2 AE 9.6 years; men/women 24/47) and HCV-infected Japanese patients with normal oral mucosa (190 patients; mean age AE standard deviation, 59.8 AE 10.0 years; men/women 83/107) who consulted Kurume University School of Medicine, Fukuoka, Japan from October 30, 2007, to January 22, 2013 (Table 1) . OLP had been diagnosed clinically and histopathologically. The sites of LP in the subjects included oral mucosa (n ¼ 65), oral and genital mucosa (n ¼ 1), oral mucosa and skin (n ¼ 3), and skin (n ¼ 2).
Moreover, a replication study was performed using Italian individuals (38 patients with LP and 7 patients with normal oral mucosa) who consulted Regional Transplantation Center, Piedmont, Molinette Hospital, Turin, Italy.
Genomic DNA was extracted from the peripheral blood of a total of 261 Japanese HCV-infected patients using the QIAamp DNA Blood Midi kit (Qiagen, Tokyo, Japan) in the Department of Virology, Liver Unit, Nagoya City University Graduate School of Medical Sciences. One microgram of purified genomic DNA was dissolved in 100 mL of TE buffer (pH 8.0) (Wako, Osaka, Japan), followed by storage at À20 C until use.
Evaluation of Liver Diseases in Japanese Patients
A total of 261 subjects were tested for their liver function. Anti-HCV was measured using a chemiluminescent enzyme immunoassay kit (Lumipulse II HCV, Fujirebio, Tokyo, Japan) and HCV RNA in serum was analyzed by quantitative polymerase chain reaction assay (COBAS Amplicor HCVv Monitor v 2.0 Test, COBAS AmpliPrep/COBAS Taq-Man HCV Test, Roche Molecular Systems, Branchburg, NJ). Ultrasonographic examination was performed on all patients. Computed tomography, liver biopsy, and endoscopic examination for esophageal or gastric varices were performed on some patients. We used other possible predictors of liver cirrhosis progression, including serum albumin, total bilirubin, prothrombin time, and platelet count.
Single-Nucleotide Polymorphism Genotyping and Data Cleaning
We genotyped 261 HCV-infected patients with or without LP using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc, Santa Clara, CA), in accordance with the manufacturer's instructions. The genotype calls for 900K single-nucleotide polymorphisms (SNPs) were determined using the Genotyping Console v4.1 software (Affymetrix, Inc, Santa Clara, CA) (with Birdseed v1 algorithm) and all samples passed a heterozygosity check. No duplication or related samples were identified by identity by descent testing. A principal component analysis was performed using 261 studied samples together with HapMap samples (including 43 JPT, 40 CHB, 91 YRI, and 91 CEU samples) AH-C, acute hepatitis C; AIH, autoimmune hepatitis; ALD, alcoholic liver disease; CH-C, chronic hepatitis C; HCC, hepatocellular carcinoma; LC-C, liver cirrhosis type C; NAFLD, nonalcoholic fatty liver disease; NS, not significant; SD, standard deviation; SVR, sustained virologic response.
(Supplementary Figure 1) . The cluster of studied samples showed overlap with that of HapMap-JPT. The average sample call rate for the 261 studied samples was 98.82% (95.26%-99.55%). Low-quality genotype data were excluded by the following thresholds for quality control: SNP call rate <95%, minor allele frequency <1%, and Hardy-Weinberg equilibrium P value < .0001. A total of 629,588 SNPs passed the threshold. The scatter plots for SNP with P < .0001 in the allelic model were then checked by visual inspection and 35 SNPs were excluded from further analysis. Finally, a total of 629,553 SNPs were used for further statistical analyses. A replication study was conducted in Italian individuals for 3 SNPs (HLA-DR/DQ rs9461799, IGFBP4 rs538399, and NRP2 rs884000) using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA) on a LightCycle 480 Real-Time PCR System (Roche, Mannheim, Germany).
Single-Nucleotide Polymorphism Imputation
Unobserved genotypes were imputed using the phased genotype data of 1000 Genomes Project reference data (Integrated Phase 3, June 2014 released) with standard software packages, such as IMPUTE version 2 (IMPUTE2) with default parameters. GTOOL was used for data format conversion from PLINK format to IMPUTE2 format. A 1-Mb window size centered on each candidate SNP was applied to impute. After imputation, the results of association test for imputed data were obtained using PLINK 1.07. SNPs with >1% missing genotype data, Hardy-Weinberg equilibrium P value ! .001 and samples including >10% missing genotype were eliminated.
Statistical Analysis
For the association tests, P values, odds ratios (ORs), and 95% confidence intervals (CIs) between the SNP and disease phenotype were assessed by chi-square test with a 2-by-2 contingency table for the allelic model. To avoid false-positive results caused by multiple testing, the significance level for the GWAS was set at P ¼ 5 Â 10 À8 . As sensitive analysis, logistic regression analysis with additive genetic model and gender and age as covariates was implemented. Figure 2) . Although no SNPs reached the genome-wide significant level (ie, P < 5 Â 10 À8 ), the greatest hit association was Figure 2 . Genome-wide view of the single-point association data based on allele frequencies in a comparison of 71 HCV Japanese patients with LP and 190 patients with HCV without OLP. P values were calculated using the chi-square test for allele frequencies among 629,553 SNPs.
Results
Genome-Wide Association Analysis
observed for rs884000, which is located about 17. Figure 3) and age-and gender-adjusted P ¼ 1.39 Â 10 À3 (OR, 2.20; 95% CI, 1.37-3.62). Here, susceptibility to or resistance against HCV related LP was evaluated by the OR for the minor allele (ie, OR >1 and OR <1 indicate susceptible and resistant alleles, respectively).
We conducted a replication analysis of candidate SNPs associated with OLP or LP in 45 Italian subjects (Supplementary Table 2 ). The replication analysis in Italian subjects did not reach significant associations, but showed the same trend of ORs as shown in Japanese subjects.
High-Density Association Mapping Based on Genotype Imputation
Genotype imputation was carried out based on genome-wide SNP typing data using the phased genotype data of the 1000 Genomes Project reference data with IMPUTE2 software packages under default parameters. Among the genetic regions including SNPs with P < 1 Â 10 À4 in the GWAS, 2 genetic regions included a SNP showing a stronger association in genotype imputation based high-density association mapping than the associations in GWAS (ie, rs884000 and rs538399) (Supplementary Figure 4) . The SNP rs538399, showing P ¼ 6.50 Â 10 À5 (OR, 0.40; 95% CI, 0.25-0.63) in the GWAS, is an intron variant of the insulin-like growth factor binding protein 4 (IGFBP4) gene.
Discussion
One of the most important issues concerning OLP is its increased potential for malignant transformation into oral squamous cell carcinoma (SCC). 2, 3 There is some evidence that HCV-positive patients with OLP might be at higher risk of malignant transformation. 27 The relative risk of malignant transformation for patients with OLP with HCV, compared with those without HCV infection, was reported to be 3.16. 27 The reported prevalence of HCV-infected patients with LP shows wide geographic variation and is high in Japan and Italy. 16, 17 We consider that the pathogenesis of OLP in HCV infection is not directly related to the virus itself, but the response generated by host factors (eg, immunologic and genetic factors and insulin resistance). Previous reports indicated that there are no differences between HCV-infected patients with LP and those without in terms of viral factors, such as viral load, genotype/subtype, and mutations leading to aa substitutions in the HCV core region (70 and/or 91) and IFN-sensitivity-determining region of nonstructural protein 5A. 28, 29 Several reports document the impact of IFN on HCVassociated OLP. As regards the effects of IFN therapy on LP lesions, there are reports of improvements in lesions, reports of LP manifestation triggered by IFN, and reports of exacerbation of LP. Especially, worsening pain and/or inflammation in OLP in patients receiving IFN therapy are particular problems that may result in the inability to complete IFN therapy. It remains difficult to predict the onset or exacerbation of OLP among HCV infectedpatients. Most recently, we reported successful treatment of HCV-infected OLP by IFN-free therapy with direct-acting antivirals. 30 We found no SNP with genome-wide significance (P < 5 Â 10
À8
). However, 2 SNPs (rs884000 in the NRP2 locus and rs538399 in the IGFBP4 locus) showed nominal associations in the GWAS and subsequent highdensity association mapping. Moreover, our genetic analysis also supported the association of the HLA class II region, including HLA-DR and DQ genes, with HCVpositive OLP. 18, 19 The 2 genetic loci found in our study and HLA genes could be useful as predictors for onset of OLP among HCV-infected patients. The replication study in Italian subjects showed the trend similar to Japanese results.
Neuropilins (NRPs), including NRP1 and NRP2, are related transmembrane receptors that function as mediators of neuronal guidance and angiogenesis. NRPs bind members of the class 3 semaphorin family (Sema3A, Sema3B, and Sema3C), regulators of neuronal guidance, and of the vascular endothelial growth factor family of angiogenesis factors. 31 NRPs function in many key biologic processes, including in the cardiovascular, nervous, and immune systems. 32 There is substantial evidence that NRPs serve as mediators of developmental and tumor angiogenesis. 31 Recent evidence suggests that NRP2 is expressed in tumor tissue and plays a role in tumor progression and metastasis. 33, 34 NRP2 is highly expressed on the surface of cancer cells from pancreatic neuroendocrine tumors, 35 colorectal carcinomas, 33 breast cancer, 36 cutaneous melanoma, 37 and oral SCC. 38 NRP2 expression also correlates with lymph node metastasis in breast cancer 36 and papillary thyroid carcinoma. 34 Cao et al 39 showed that NRP2 promotes metastasis of renal cell carcinoma (RCC) and pancreatic cancer in mouse and zebrafish models and showed a mechanism through which NRP2 expressed on cancer cells interacts with a-5 integrin on endothelial cells to mediate vascular adhesion and extravasation.
The insulin-like growth factor system (IGFs) consists of 2 peptides (IGF-I and -II), 2 main receptors (IGF-IR and IGFIIR), 6 different IGF binding proteins (IGFBP1-6), and 4 IGFBP-related peptides (IGFBP Rp1-4). IGFs have multiple functions regarding cellular growth, survival, and differentiation under different physiologic and pathologic conditions. 40 IGFBP4 is an important member of the IGF system. IGFBP4 has been reported to play a critical role in cardiomyocyte differentiation of embryonic stem cells. 41 Several cancer cell lines, including from multiple myeloma, neuroblastoma, and mesothelioma, and cancers of the lung, gastric, thyroid, breast, prostate, and colon have been reported to express IGFBP4. 42 Ueno et al 43 initially showed that the expression of IGFBP4 was significantly lower in primary RCC and higher in metastatic RCC, compared with normal human kidney tissue, and that IGFBP4 transfectants promoted cell growth (in vitro and in vivo), invasion, and motility in primary RCC.
In the present study, 4 of 71 Japanese patients with LP (5.6%), 3 women and 1 man, developed oral SCC. One of the 4 subjects was a 84-year-old woman who suffered from HCV-related liver cirrhosis. She developed oral verrucous carcinoma, arising OLP-coexisting vulvo-vaginal gingival syndrome and esophageal SCC. 44 Another, in whom sustained virologic response was obtained by IFN therapy, was a 73-year-old man who suffered from chronic hepatitis C and hypertension. He developed tongue cancer and Graves ophthalmopathy during pegylated IFN plus ribavirin therapy. The third patient was a 57-year-old woman who suffered from chronic hepatitis C during IFN therapy. She developed tongue cancer arising from OLP. The fourth was a 67-year-old woman who suffered from chronic hepatitis C. She developed tongue cancer arising from OLP after treatment with pegylated IFN plus ribavirin. Only she had the risk allele at rs88400 in NRP2 but she did not have the resistance allele at rs538399 in IGFBP4. No patients in the control group developed oral cancer.
We reported previously that insulin resistance might be involved in the development of multiple primary cancers in patients with oral SCC and HCV infection 45 and might cause OLP and extrahepatic manifestations. 46, 47 The prevalence of extrahepatic malignant tumors was significantly higher in patients with OLP (29.4%) than in patients without (4.3%). 47 Two SNPs (rs884000 on NRP2 and rs538399 on IGFBP4) may play a role in the malignant transformation of OLP.
Our study had some limitations. The sample size was relatively smaller than that for the conventional GWAS for diagnostic criteria. However, to the best of our knowledge, our GWAS for HCV-related LP is the first such report.
In conclusion, we identified novel associations of rs884000 in NRP2, rs538399 on IGFBP4, and supported the association of the HLA-DR/DQ genes, with HCVpositive LP in the Japanese and Italian population. Our data suggest that these genes may be involved in the development of LP and malignant transformation and useful as a predictive marker for the onset of OLP with IFN therapy among HCV infected-patients. 
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